Figure 2. Number of patients initiated on a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor among different patient groups with atherosclerotic cardiovascular disease (ASCVD).

The orange bars represent the number of patients started on a PCSK9 inhibitor, and the blue bars represent the number of patients not started on PCSK9 inhibitor therapy, among different patient groups with ASCVD. LDL indicates low‐density lipoprotein.